Recent News

  1. Jubilant Pharma Limited (“JPL”) a wholly owned subsidiary of Jubilant Life Sciences Ltd. through one of its subsidiaries announced today that it has signed an Agreement to acquire substantially all of the assets which comprise the radiopharmacy business of Triad Isotopes Inc. (“Triad”). See notification below.
  2. Jubilant DraxImage had significant presence at this year’s Mid-Winter meeting featuring important information on  V/Q imaging (MAA), Radioiodine therapy (HICON) and most importantly introducing its newest product approved by the USFDA; RubyFill.
  3. Jubilant Pharma, a solutions provider to global pharmaceutical customers, announced today it has appointed Michael Rossi as President of Jubilant DraxImage. Jubilant Pharma announced today it has appointed Michael Rossi as President of Jubilant DraxImage effective immediately. Michael will be responsible for leading the Jubilant DraxImage business, a subsidiary of (...)
  4. RUBY-FILL® is an approved cutting edge technology for PET myocardial perfusion imaging (MPI) under rest and pharmacological stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease. MONTREAL, Quebec – October 3, 2016 Jubilant DraxImage Inc., (“DraxImage”) a wholly Owned Subsidiary of Jubilant (...)
  5. JDI clarifies: no impact on supply from Chalk River shutdown JDI has received  enquiries from its customers with regards to our supply of I-131 following the announcement of the closure of the Chalk River reactor. JDI wishes to inform its customers purchasing JDI I-131 that JDI does not anticipate any (...)
  6. Jubilant DraxImage and Cyclopharm Terminate Technegas Licensing Agreement Negotiations MONTREAL, Quebec – May 12, 2016 –  Jubilant DraxImage (“DraxImage”) announced today that despite several months of negotiations, it and Cyclopharm (ASX: CYC) (“CYC”) have terminated their negotiations of an exclusive license agreement for the development and marketing of CYC’s lung (...)
  7. Jubilant DraxImage launches “Not all Iodine-131 is created equal” Campaign Jubilant DraxImage is pleased to announce the launch of its “Not all Iodine-131 is created equal” campaign. We wish to raise awareness about the differences between FDA approved pharmaceutical-grade I-131 drug products such as Jubilant DraxImage’s HICON® I-131 and radiochemical-grade (...)
  8. Jubilant DraxImage launches Count On It DRAXIMAGE® MAA 350K Particles Campaign Jubilant DraxImage is pleased to announce the launch of its Count On It DRAXIMAGE® MAA 350K Particles Campaign. The campaign speaks primarily to radiopharmacists and Nuclear Medicine technologists that prepare unit doses of DRAXIMAGE® MAA for use in patients (...)
  9. JDI releases a patient video to demystify the role of Radioactive Iodine in the treatment of Differentiated Thyroid Cancer (DTC) Jubilant DraxImage is pleased to announce the launch of its first video series focused on one of the fastest growing cancers in North America: thyroid cancer. The production of this (...)
  10. JDI releases a patient video to demystify the role of Radioactive Iodine in the treatment of Differentiated Thyroid Cancer (DTC) Jubilant DraxImage is pleased to announce the launch of its first video series focused on one of the fastest growing cancers in North America: thyroid cancer. The production of this (...)
  11. Jubilant DraxImage signs Term Sheet with Cyclopharm for exclusive license to market Technegas in the United States Montreal & Sydney, September 14, 2015 – Jubilant DraxImage Inc. (“DraxImage”) and Cyclopharm Limited (“CYC”) are pleased to announce the signing of a term sheet, subject to satisfactory due diligence and  execution of (...)
  12. JDI supports Thyroid Cancer Canada and Thyroid Cancer Survivors’ Association (US) in their educational endeavour… Jubilant DraxImage is thrilled to host Thyroid Cancer survivors, representatives of these organizations, as well as a world renowned expert in the field of radioiodine ablation therapy. A big welcome goes to Marie-Hélène Caron, Jennifer (...)
  13. Come meet us and listen to fireside chats between KOLs and Dr. Norman LaFrance Come meet us and listen to fireside chats between KOLs and Dr. Norman LaFrance throughout the conference about cardiac PET imaging and its promise to improve patient care. For more information, see the schedule at the booth. (...)
  14. We are pleased to announce the hiring of Mr. James Lalli, as Endocrine Brand Portfolio Manager, as of July 6th, 2015. In his new role, James will be responsible for the lifecycle management of iodine-131 diagnostic and therapeutic, HICON®, SMART-FILLTM, and MIBG. James will be reporting to Suzanne Bissonnette and (...)